EBS Q1 2022 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$308M-10.3% YoY

Gross Profit

$106M34.4% margin

Operating Income

$6M2.1% margin

Net Income

-$4M-1.2% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-57.5%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$70M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$2.8B

Total Liabilities

$1.2B

Stockholders' Equity

$1.6B

Cash & Equivalents

$436M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$308M	$343M	-10.3%
Gross Profit	$106M	$192M	-45.0%
Operating Income	$6M	$95M	-93.3%
Net Income	-$4M	$70M	-105.3%

Revenue Segments

Product

$237M77%

Contract Development And Manufacturing

$61M20%

Contracts and Grants

$10M3%

Geographic Segments

Non-US

$195M63%

UNITED STATES

$113M37%